Clinical Trials · NCT06500429
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Neurogastrx, Inc.
- Enrollment
- 120
- Start date
- Jun 2024
- Locations
- 1 site, United States
- Primary endpoint
- Duration of GI-related adverse events